with electrophysiological parameters and antibody testing.
Electrophysiology testing demonstrates the characteristic so-called Lambert triad, including:
• reduced amplitudes of the compound muscles action potential (CMAP) in the motor conduction velocity studies;
• decremental responses of the CMAP amplitudes to low-frequency (2-3 Hz) repetitive nerve stimulation; and
• marked incremental responses of the CMAP amplitudes to high-frequency repetitive nerve stimulation or voluntary muscle contraction over a brief period of time. 15 If the facilitation is greater than 100 % in most muscles tested or is greater than 400 % in any muscle, the patient almost certainly has LEMS.
If facilitation is less than 50 % in all muscles tested, the patient still may have LEMS, especially if symptoms have been present for only a short time. 4 The diagnosis of LEMS may be confirmed by radioimmunoassay of VGCC antibodies which are believed to be the main pathogenic factors in LEMS, 16 and these are detected in 85 % of patients with clinically and electrophysiologically defined LEMS. 17, 18 In seronegative LEMS patients without detectable VGCC antibodies, the electrophysiological findings are less pronounced. 19 Because of the high prevalence of SCLC in LEMS, it is mandatory to perform a careful tumour screening, especially in 
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Current Treatments for Lambert-Eaton Myasthenic Syndrome
The most widely used treatment for symptom relief of LEMS is 3,4-diaminopyridine (3,4-DAP, amifampridine), which was first suggested to improve muscle strength and autonomic function in a small case series of LEMS patients more than 25 years ago. 24 3,4-DAP blocks potassium ion channels in membranes and facilitates synaptic transmission. 25 The blocking of potassium ion channels prolongs the depolarisation during nerve action potentials, thereby increasing the open-time of voltage-gated calcium channels and consequently the influx of calcium ions into the nerve terminal. This increased calcium influx enhances the quantal neurotransmitter release which is calcium dependant. Both 4-aminopyridine and 3,4-DAP have been used to treat LEMS, but 4-aminopyridine is thought to be less effective and has a narrow toxic to therapeutic margin, 26 with many neurological side effects reported. 27 Due to the rarity of the condition, few randomised controlled trials (RCTs) involving LEMS therapies have been conducted.
The potassium channel blocker guanidine hydrochloride has shown limited efficacy in some small studies but it is associated with gastrointestinal, renal and haematological adverse events. 27, 28 Cholinesterase results and support their wider use. [31] [32] [33] Only one RCT involving these therapies has been carried out. It compared IVIG with placebo in LEMS patients and found significant but short-term improvement of limb, respiratory and bulbar muscle strength. 33 Immunosuppressive therapies such as prednisolone or azathioprine have shown efficacy in LEMS but the proportions of patients showing improvements were limited and the effects were short-lived. [34] [35] [36] [37] In LEMS patients corticosteroids can be used when required for the disease treatment; however, immunosuppressants should be avoided before the presence of a tumour is ruled out. 38 As in other autoimmune disorders, the anti-CD 20 antibody rituximab is a promising agent also for LEMS. However, there are still only scattered reports on the use of rituximab in LEMS patients. 35, 39 A recently published retrospective data survey including ten patients with myasthenia gravis and two patients with LEMS, found that rituximab treatment resulted in a significant clinical improvement in two-thirds of cases. 39 The data from this survey showed that both LEMS patients improved clinically, however, they did not achieve remission.
Anti-tumour treatments are essential for all patients with the paraneoplastic form of LEMS to treat underlying malignancies. 40 Interestingly, data supports a role for the LEMS-related immune response in suppressing tumour activity which can prolong the survival time of LEMS patients with cancer. 41, 42 Chemotherapeutic agents, such as vincristine, doxorubicin, adriamycine and cyclophosphamide, have shown efficacy against SCLC-associated LEMS but the proportions of patients benefiting were small. 34, 37 Chalk et al. 37 evaluated the outcome of 16 patients with LEMS associated with small-cell carcinoma.
Thirteen patients received specific tumour therapy and most also received pharmacological and immunological treatment for LEMS.
Seven of 11 patients surviving for more than two months after tumour
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All the studies showed that 3,4-DAP was generally well tolerated with a favourable risk:benefit ratio. Few adverse effects were reported, and these were mild, transient and dose-related, and included paraesthesia, heat sensation, difficulty sleeping, light-headedness and fatigue. 
The Problem of Compounding 3,4-diaminopyridine
The use of compounded drug products, produced by the ad hoc mixing of drugs tailored to the specialised medical need of the patient, are still widespread in independent community pharmacies. 56 The practice is controversial because, by definition, it involves producing a drug for The quality of compounded drugs creates an important public health concern and is of particular relevance for 3,4-DAP because until recently it has only been available as a compounded product. Its use requires local, hospital or other pharmacies to prepare tablets or capsules from the base compound. 64 These are used either orally or in the preparation of solutions for intravenous administration. Raust et al.
demonstrated that the base form of 3,4-DAP is much less stable under stress conditions than the salt formulation of 3,4-DAP, with 27 % of the base form degraded compared with only 0.1 % of the salted form. 64 As there exists potential instability of the base compound (which is only stable for up to 12 months) and potential compounding errors in manufacture, these issues have implications for the efficacy and safety of the product. Furthermore, compounded forms of 3,4-DAP do not have appropriate safety monitoring and pharmacovigilance systems in place to capture, analyse and report efficacy and safety data. It is evident from these data that compounded formulations of 3,4-DAP can vary widely and that patients may be exposed to unnecessary risks. There is a need for pharmaceutical grade oral dosage forms of 3,4-DAP to ensure efficacy and patient safety (see Figure 3) . As a result of a recent review of available efficacy and safety data, 3,4-DAP has been recommended as a first-line treatment of symptomatic LEMS by the European Federation of Neurological Societies. 53 The salt species of 3,4-DAP has been shown to have superior stability compared to the base, 64 and an oral formulation containing 3,4-DAP phosphate salt, equivalent to 10 mg base, is now available. This formulation has obtained the orphan medicinal product status both in the European Union and in the US, and has received marketing authorisation in Europe as Firdapse ® . Although the safety and efficacy of 3,4-DAP phosphate has not been directly compared with 3,4-DAP base in a RCT, it has been shown to be essentially bioequivalent with the base preparation, 67 and has been produced with vigorous quality control and pharmacovigilance standards as required by regulators.
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